Molecular pathways and therapeutic targets in lung cancer

Lung cancer is still the leading cause of cancer death worldwide. Both histologically and molecularly lung cancer is heterogeneous. This review summarizes the current knowledge of the pathways involved in the various types of lung cancer with an emphasis on the clinical implications of the increasing number of actionable molecular targets. It describes the major pathways and molecular alterations implicated in the development and progression of non-small cell lung cancer (adenocarcinoma and squamous cancer), and of small cell carcinoma, emphasizing the molecular alterations comprising the specific blueprints in each group. The approved and investigational targeted therapies as well as the immune therapies, and clinical trials exploring the variety of targeted approaches to treatment of lung cancer are the main focus of this review.

• Publication year

  2014

• Venue

  OncoTarget

• Publication date

  2014-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.18632/ONCOTARGET.1891PMID 24722523PMCID 4039220
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer

  2014influential reference
• Wnt signaling pathway in non-small cell lung cancer.

  2014cited by this paper
• Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.

  2014cited by this paper
• MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.

  2014cited by this paper
• Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

  2014cited by this paper
• Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.

  2014cited by this paper
• The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma.

  2014cited by this paper
• A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer.

  2014cited by this paper
• Targeting SOD1 reduces experimental non–small-cell lung cancer.

  2014cited by this paper
• Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation.

  2014cited by this paper
• Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.

  2014cited by this paper
• Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

  2014cited by this paper
• Ectopic Activation of Germline and Placental Genes Identifies Aggressive Metastasis-Prone Lung Cancers

  2013cited by this paper
• Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung

  2013cited by this paper
• A Genomics-Based Classification of Human Lung Tumors

  2013cited by this paper
• The quest to overcome resistance to EGFR-targeted therapies in cancer

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer

  2013cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013influential reference
• Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story.

  2013cited by this paper
• Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

  2013cited by this paper
• VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.

  2013cited by this paper
• LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.

  2013cited by this paper
• Requirement for Interaction of PI3-Kinase p110 alpha with RAS in Lung Tumor Maintenance

  2013cited by this paper
• EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma

  2013cited by this paper
• Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer

  2013cited by this paper
• Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

  2013cited by this paper
• Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer

  2013cited by this paper
• Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

  2013cited by this paper
• The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα.

  2013cited by this paper
• Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

  2013cited by this paper
• Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

  2013cited by this paper
• Acquired resistance to crizotinib from a mutation in CD74-ROS1.

  2013cited by this paper
• Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

  2013cited by this paper
• Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance

  2013cited by this paper
• Inhibitors of Hedgehog Acyltransferase Block Sonic Hedgehog Signaling

  2013cited by this paper
• Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

  2013cited by this paper
• Genomic landscape of non-small-cell lung cancer in smokers and never-smokers

  2013cited by this paper
• Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer.

  2013cited by this paper
• Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas

  2013cited by this paper
• Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

  2013cited by this paper
• KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.

  2013cited by this paper
• Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

  2013cited by this paper
• Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors.

  2013cited by this paper
• ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

  2013cited by this paper
• Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

  2013cited by this paper
• Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data

  2013cited by this paper
• Reply to F. Gelsomino et al.

  2013cited by this paper
• Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

  2013cited by this paper
• Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

  2013cited by this paper
• Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

  2013cited by this paper
• Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer

  2013cited by this paper
• Harnessing the immune system for the treatment of non-small-cell lung cancer.

  2013cited by this paper
• Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

  2013cited by this paper
• Molecular Pathways Molecular Pathways : ROS 1 Fusion Proteins in Cancer

  2013cited by this paper
• Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells.

  2013cited by this paper
• Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.

  2013influential reference
• Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer

  2013cited by this paper
• Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

  2013cited by this paper
• Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC

  2013cited by this paper
• CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

  2013cited by this paper
• Acquired resistance to crizotinib from a mutation in CD74-ROS1.

  2013cited by this paper
• Lkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas

  2013cited by this paper
• Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer

  2013cited by this paper
• EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance.

  2013cited by this paper
• Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer.

  2013cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins

  2013influential reference
• A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop

  2013cited by this paper
• Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.

  2013cited by this paper
• Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

  2013cited by this paper
• Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.

  2013cited by this paper
• A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.

  2013cited by this paper
• Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer

  2013influential reference
• The Involvement of NRF2 in Lung Cancer

  2013cited by this paper
• Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

  2013cited by this paper
• Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer

  2013cited by this paper
• Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma.

  2013cited by this paper
• Elucidating distinct roles for NF1 in melanomagenesis.

  2013cited by this paper
• A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal.

  2013cited by this paper
• K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

  2013cited by this paper
• LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.

  2013cited by this paper
• USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer

  2013cited by this paper
• Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

  2013cited by this paper
• IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations

  2013cited by this paper
• Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

  2013cited by this paper
• Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

  2013cited by this paper
• Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer

  2013cited by this paper
• Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction.

  2013cited by this paper
• FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma.

  2013cited by this paper
• A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

  2013influential reference
• Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.

  2013cited by this paper
• Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.

  2013cited by this paper
• Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

  2013influential reference
• The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth

  2013cited by this paper
• Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

  2013cited by this paper
• Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.

  2013cited by this paper
• Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.

  2013cited by this paper
• GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability

  2013cited by this paper
• Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

  2013cited by this paper

• Therapeutic Efficacy Studies on the Monoterpenoid Hinokitiol in the Treatment of Different Types of Cancer

  2025cites this paper
• The role of Wnt/β-catenin signaling in lung cancer progression and therapy: a comprehensive review

  2025cites this paper
• Aging-associated alterations in gene regulatory networks associate with risk, prognosis and response to therapy in lung adenocarcinoma

  2025cites this paper
• Integrating Immunotherapy With Targeted Therapy: Evaluating Efficacy in NSCLC Treatment Through Computational Analysis of Gene Regulatory Networks

  2025cites this paper
• Pollutants as Hidden Triggers: A Computational View on Oral and Lung Cancer Development

  2025cites this paper
• Mechanistic insights into molecular targeted therapy and immunotherapy for lung cancer.

  2025cites this paper
• Targeting Lung Cancer With Carvacrol‐Triazole‐Arylidene Hydrazide Hybrids: In Vitro and In Silico Cytotoxicity Assessments

  2025cites this paper
• Targeted drug conjugates and molecular mechanisms in overcoming lung cancer drug resistance

  2025cites this paper
• An Observational Study of Clinical Profile and Outcomes of Nonsmall Cell Lung Cancer Patients

  2025cites this paper
• Machine learning for genomic profiling and drug discovery in personalised lung cancer therapeutics

  2025cites this paper
• Effectiveness of Artificial Intelligence Models in Predicting Lung Cancer Recurrence: A Gene Biomarker-Driven Review

  2025cites this paper
• Cellular Senescence in Lung Cancer: Molecular Mechanisms and Therapeutic Interventions.

  2024cites this paper
• Gene regulatory networks reveal sex difference in lung adenocarcinoma

  2024cites this paper
• Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications.

  2024cites this paper
• Aging-associated Alterations in the Gene Regulatory Network Landscape Associate with Risk, Prognosis and Response to Therapy in Lung Adenocarcinoma

  2024cites this paper
• Exploring molecular mechanisms of diazinon toxicity in HT22 hippocampal neurons through integrated miRNA and mRNA profiling

  2024cites this paper
• Water‐Soluble Curcumin Derivatives Including Aza‐Crown Ether Macrocycles as Enhancers of Their Cytotoxic Activity

  2024cites this paper
• Curcuma Longa Phytocompounds: An in Silico Analysis Aimed at Targeting the EGFR Protein as a Potential Anti-cancer Agent

  2024cites this paper
• KIAA1429-mediated RXFP1 attenuates non-small cell lung cancer tumorigenesis via N6-methyladenosine modification.

  2024cites this paper
• Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?

  2024cites this paper
• Identification of genetic associations between acute myocardial infarction and non-small cell lung cancer

  2024cites this paper
• Analysis and Review of Downregulated Actin Cytoskeletal Proteins in Non-Small Cell Lung Cancer

  2024cites this paper
• Comparative Analysis of Mutation in the Buccal Epithelium and Blood in Patients with Lung Cancer and Healthy People

  2024cites this paper
• Exosomal PVRL4 Promotes Lung Adenocarcinoma Progression by Enhancing the Generation of Myeloid‐Derived Suppressor Cell‐Secreted TGF‐β1

  2024cites this paper
• [Licochalcone A induces cell cycle arrest in human lung squamous carcinoma cells via the PI3K/Akt signaling pathway].

  2023cites this paper
• Allium ampeloprasum leaf aqueous extract green-formulated Ag nanoparticles: Determination of anti-human lung cancer and antioxidant effects

  2023cites this paper
• Lung Cancer – Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators

  2023cites this paper
• A 15-Gene-Based Risk Signature for Predicting Overall Survival in SCLC Patients Who Have Undergone Surgical Resection

  2023cites this paper
• A Novel Feature Engineering Method Based on Latent Representation Learning for Radiomics: Application in NSCLC Subtype Classification

  2023cites this paper
• Integrated bioinformatics analyses identifying key transcriptomes correlated with prognosis and immune infiltrations in lung squamous cell carcinoma

  2023cites this paper
• The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer

  2023cites this paper
• Radiomics feature analysis and model research for predicting histopathological subtypes of non-small cell lung cancer on CT images: a multi-dataset study.

  2023cites this paper
• Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis

  2023cites this paper
• Gene regulatory Networks Reveal Sex Difference in Lung Adenocarcinoma

  2023cites this paper
• A review on emerging role of multifunctional carbon nanotubes as an armament in cancer therapy, imaging and biosensing

  2023cites this paper
• Femoral metastatic pathological fractures, impending and actual fractures - A patient survival study.

  2023cites this paper
• Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing

  2022cites this paper
• Diosgenin promotes cisplatin‐induced apoptosis through oxidative DNA damage in A549 non‐small cell lung cells

  2022cites this paper
• Construction of a prognostic model for lung squamous cell carcinoma based on immune-related genes.

  2022cites this paper
• Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

  2022cites this paper
• miR-4731-5p Enhances Apoptosis and Alleviates Epithelial-Mesenchymal Transition through Targeting RPLP0 in Non-Small-Cell Lung Cancer

  2022cites this paper
• The Role of Hydrogen Sulfide in the Development and Progression of Lung Cancer

  2022cites this paper
• Lymphocyte percentage as a valuable predictor of prognosis in lung cancer

  2022cites this paper
• GANT61/BI-847325 combination: a new hope in lung cancer treatment

  2022cites this paper
• EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones

  2022cites this paper
• Tumor-specific imaging probes in preclinical applications and clinical trials

  2022cites this paper
• Integrated omics profiling and network pharmacology uncovers the prognostic genes and multi-targeted therapeutic bioactives to combat lung cancer.

  2022cites this paper
• Quantum Algorithm for the Simulation of Squamous Cell Lung Carcinoma tested through IBM Quantum Composer

  2022cites this paper
• Vorinostat Reverses Paclitaxel Resistance Induced by SIRT6 Upregulation Through Enhancing Autophagy in Lung Cancer

  2022cites this paper
• β-Elemene Restrains PTEN mRNA Degradation to Restrain the Growth of Lung Cancer Cells via METTL3-Mediated N6 Methyladenosine Modification

  2022cites this paper
• MiR‐630 suppresses non‐small cell lung cancer by targeting vimentin

  2022cites this paper
• Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer

  2022cites this paper
• Purpurin, a anthraquinone induces ROS-mediated A549 lung cancer cell apoptosis via inhibition of PI3K/AKT and proliferation.

  2021cites this paper
• Low Expression of SCN4B Correlated with DNA Hypermethylation and Poor Prognosis in Non-small Cell Lung Cancer

  2021cites this paper
• PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells

  2021cites this paper
• COVID-19 candidate genes and pathways potentially share the association with lung cancer.

  2021cites this paper
• Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients

  2021cites this paper
• The misuse of distributional assumptions in functional class scoring gene-set and pathway analysis

  2021cites this paper
• Role of Oxidative Stress and DNA Damage/Repair in Lung Cancer

  2021cites this paper
• Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma

  2021cites this paper
• Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?

  2021cites this paper
• SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition.

  2021cites this paper
• An anti-EGFR/anti- HER2 Bispecific Antibody with Enhanced Antitumor Activity Against Acquired Gefitinib-Resistant NSCLC Cells.

  2021cites this paper
• The impact of distributional assumptions in gene-set and pathway analysis: how far can it go wrong?

  2021cites this paper
• Long noncoding RNA SNHG20 regulates cell migration, invasion, and proliferation via the microRNA-19b-3p/RAB14 axis in oral squamous cell carcinoma

  2021cites this paper
• How Different Substitution Positions of F, Cl Atoms in Benzene Ring of 5-Methylpyrimidine Pyridine Derivatives Affect the Inhibition Ability of EGFRL858R/T790M/C797S Inhibitors: A Molecular Dynamics Simulation Study

  2020cites this paper
• FAM136A immunoreactivity is associated with nodal involvement and survival in lung adenocarcinoma in a Chinese case series.

  2020cites this paper
• Role of Non-Coding RNAs and Metabolism in Lung Cancer

  2020cites this paper
• Multifaceted Roles of Caveolin-1 in Lung Cancer: A New Investigation Focused on Tumor Occurrence, Development and Therapy

  2020cites this paper
• A general kernel boosting framework integrating pathways for predictive modeling based on genomic data

  2020cites this paper
• HSPA1L Enhances Cancer Stem Cell-Like Properties by Activating IGF1Rβ and Regulating β-Catenin Transcription

  2020cites this paper
• Cellular retinol binding protein 1 transfection reduces proliferation and AKT-related gene expression in H460 non-small lung cancer cells

  2020cites this paper
• LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway

  2020cites this paper
• Protein arginine methyltransferase-5  Selective Inhibitor Enhances Therapeutic Effects of Cisplatin on Lung Cancer Cells

  2020cites this paper
• Correlation between MMP2 expression in lung cancer tissues and clinical parameters: a retrospective clinical analysis

  2020cites this paper
• Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting—Role of Academic and Hybrid Modeling

  2020cites this paper
• Advances in Small-Cell Lung Cancer (SCLC) Translational Research.

  2020cites this paper
• Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

  2020cites this paper
• Increased MMP2 contributes to the diagnosis and prognosis of lung cancer

  2020influential citation
• A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.

  2020cites this paper
• Knockdown of TRAP1 promotes cisplatin-induced apoptosis by promoting the ROS-dependent mitochondrial dysfunction in lung cancer cells

  2020cites this paper
• PenDA, a rank-based method for personalized differential analysis: Application to lung cancer

  2020influential citation
• Comprehensive transcriptomic analysis identifies novel regulators of lung adenocarcinoma

  2020cites this paper
• first‐line treatment for patients with advanced non‐small cell lung cancer (NSCLC) ineligible for biological therapy, notwith-

  2020cites this paper
• CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells

  2020cites this paper
• Herbal extract of Artemisia maritima induces selective anti-tumor effects in three human lung carcinoma cells (H1299, NCI-H1437, PC-14) through activating apoptosis-related proteins, G2/M cell cycle arrest and suppression of cell migration.

  2020cites this paper
• 2-[18F]FDG PET/CT radiomics in lung cancer: an overview of the technical aspect and its emerging role in management of the disease.

  2020cites this paper
• Non-Coding RNAs in Lung Tumor Initiation and Progression

  2020influential citation
• Hispidulin exhibits potent anticancer activity in vitro and in vivo through activating ER stress in non-small-cell lung cancer cells

  2020cites this paper
• Gene microarray expression profile analysis of differentially expressed genes of potential alternative pathways in non–small cell lung cancer: In search of biomarkers

  2020cites this paper
• Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications

  2020cites this paper
• Silence of S1 RNA binding domain 1 represses cell growth and promotes apoptosis in human non-small cell lung cancer cells.

  2019cites this paper
• Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).

  2019cites this paper
• A probabilistic method for leveraging functional annotations to enhance estimation of the temporal order of pathway mutations during carcinogenesis

  2019cites this paper
• The Effects of EGFR Exon 19 747–750 Deletion on the Risk of Developing Lung Cancer

  2019cites this paper
• Deep Learning Enhancing Kinome-Wide Polypharmacology Profiling: Model Construction and Experiment Validation.

  2019cites this paper
• Overexpression of immunohistochemical RhoA associated with poor prognosis in operable non-small cell lung cancer

  2019cites this paper
• Non-coding RNA and Lung Cancer Progression.

  2019cites this paper
• High NF-E2-related factor 2 expression predicts poor prognosis in patients with lung cancer: a meta-analysis of cohort studies

  2019cites this paper
• Hemophagocytic syndrome as the initial manifestation of CD20(+) B-cell non-Hodgkin lymphoma with EGFR(+) lung adenocarcinoma: a case report and literature review

  2019cites this paper